Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2019 | NKG2D CARs for R/R AML and MDS

David Sallman • 14 Jun 2019
EHA 2019
Acute Myeloid Leukemia Myelodysplastic Syndromes

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the use of NKG2D CARs for relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from David Sallman

HMA maintenance therapy in TP53-mutated AML and MDS improves outcomes of transplantation
1:32
HMA maintenance therapy in TP53-mutated AML and MDS improves outcomes of transplantation
David Sallman • 5 Dec 2025
Pivekimab sunirine in combination with venetoclax plus azacitidine in unfit, newly diagnosed AML
2:19
Pivekimab sunirine in combination with venetoclax plus azacitidine in unfit, newly diagnosed AML
David Sallman • 5 Dec 2025
Advances in menin inhibition for AML: experience with revumenib and recent approval of ziftomenib
1:56
Advances in menin inhibition for AML: experience with revumenib and recent approval of ziftomenib
David Sallman • 5 Dec 2025
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
16:15
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
David Sallman • 19 Sep 2025

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
David Sallman • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
David Sallman • 6 Dec 2025
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
3:16
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
David Sallman • 6 Dec 2025
Preliminary results with 7 versus 14-day emavusertib plus aza-ven in AML
2:16
Preliminary results with 7 versus 14-day emavusertib plus aza-ven in AML
David Sallman • 17 Dec 2025
The content of VJHemOnc is intended for healthcare professionals